Mangoceuticals, Inc. (MGRX)
| Market Cap | 7.65M -61.0% |
| Revenue (ttm) | 414,579 -26.0% |
| Net Income | -20.38M |
| EPS | -1.56 |
| Shares Out | 16.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502,517 |
| Open | 0.4369 |
| Previous Close | 0.4380 |
| Day's Range | 0.4187 - 0.4800 |
| 52-Week Range | 0.1620 - 2.7500 |
| Beta | 2.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 5, 2026 |
About MGRX
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and acc... [Read more]
Financial Performance
In 2025, Mangoceuticals's revenue was $456,021, a decrease of -25.96% compared to the previous year's $615,873. Losses were -$21.82 million, 129.5% more than in 2024.
Financial StatementsNews
Mangoceuticals Quarterly report: Q1 2026
Mangoceuticals has published its Q1 2026 quarterly earnings report on May 19, 2026.
Mangoceuticals Annual report: Q4 2025
Mangoceuticals has published its Q4 2025 annual report on April 1, 2026.
Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?
Mangoceuticals, Inc. ($MGRX) stock rocketed higher on Monday alongside a filing with the Securities and Exchange Commission (SEC) from the men’s wellness products and services company. This filing upd...
Mangoceuticals files civil lawsuit against Clarity Ventures
Mangoceuticals (MGRX) announced that it has filed a civil lawsuit against Clarity Ventures, its former technology consulting and software development firm. The lawsuit, filed in Texas state court, see...
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health an...
Mangoceuticals announces patent filing for MGX-0024
Mangoceuticals (MGRX) “announced the filing of a Patent Cooperation Treaty (PCT) international application on February 26, 2026, to secure broad global patent protection for the antiviral animal feed ...
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telem...
Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure teleme...
Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today
Mangoceuticals stock saw strong momentum today alongside positive results from its TRT program.
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a c...
Mangoceuticals Registration statement: Registration Filing
Mangoceuticals filed a registration statement on January 23, 2026, providing details about a securities offering with the SEC.
Mangoceuticals files to sell 2.64M shares of common stock for holders
17:33 EST Mangoceuticals (MGRX) files to sell 2.64M shares of common stock for holders
Mangoceuticals Registration statement: Registration Filing
Mangoceuticals filed a registration statement on January 13, 2026, providing details about a securities offering with the SEC.
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements
DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via...
Mangoceuticals, Cube Group partner for up to $100M Solana-focused DAT strategy
Mangoceuticals (MGRX) announced an up to $100M Solana (SOL-USD)-focused digital asset treasury, DAT, strategy in partnership with Cube Group, through its newly formed subsidiary, Mango DAT. This initi...
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on d...
Mangoceuticals announces $2.5M registered direct, private placements
Mangoceuticals (MGRX) entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a ...
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules
DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via...
Mangoceuticals Quarterly report: Q3 2025
Mangoceuticals has published its Q3 2025 quarterly earnings report on November 14, 2025.
Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership
Investors continued to dump shares of telehealth company Mangoceuticals ($MGRX) during early trading on Friday. This came after pharmaceutical heavyweights Eli Lilly ($LLY) and Novo Nordisk ($NVO) den...
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc.
Novo denies partnership with Mangoceuticals on obesity drug, Reuters says
Novo Nordisk (NVO) and Eli Lilly (LLY) do not have a weight-loss drug partnership with telehealth website Mangoceuticals (MGRX), spokespeople for both companies said, rejecting a press release issued ...
Eli Lilly says ‘no affiliation’ with Mangoceuticals
Eli Lilly (LLY) said it “has no affiliation with Mangoceuticals. Any communication or media report suggesting a partnership between Lilly and Mangoceuticals is false. In fact, Lilly sued Mangoceutical...
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company...
Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk
Shares of Mangoceuticals ($MGRX), the Texas-based telehealth company focused on men’s health, rose sharply in early trading on Thursday, climbing 24.43% to $2.19 per share. This came after the company...